This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Viral Infections  • Pediatrics  • Neonatology and Infant Care  • Immunization  • World Health  • Gastroenterology  • Liver/ Biliary Tract/ Pancreatic Diseases  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

JAMA. 2007;298:506-509.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MMWR. 2007;56:441-445

3 figures omitted

Hepatitis B virus (HBV) infection is a leading cause of illness and death in China. Approximately 60% of the population has a history of HBV infection, and 9.8% of persons in China are chronically infected with HBV and at risk for premature death from liver disease.¹ Each year, an estimated 263,000 persons in China die from HBV-related liver cancer or cirrhosis, accounting for 37%-50% of HBV-related deaths worldwide.² Because most HBV infections occur during infancy or early childhood, when HBV infection is most likely to become chronic, vaccination of infants beginning at birth is the key strategy for preventing chronic HBV infection. This report describes China's progress in increasing coverage among infants with hepatitis B vaccine (HepB) and timely administration of the HepB birth dose (i.e., within 24 hours of birth). Infant vaccination coverage with both the timely birth dose and the complete vaccine series . . . [Full Text of this Article]

Hepatitis B Immunization Program



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?